Loxoprofen: A Review in Pain and Inflammation

详细信息    查看全文

• 作者：Sarah L. Greig ; Karly P. Garnock-Jones
• 刊名：Clinical Drug Investigation
• 出版年：2016
• 出版时间：September 2016
• 年：2016
• 卷：36
• 期：9
• 页码：771-781
• 全文大小：591 KB
• 刊物主题：Pharmacotherapy; Pharmacology/Toxicology; Internal Medicine;
• 出版者：Springer International Publishing
• ISSN：1179-1918
• 卷排序：36

文摘

Loxoprofen (Loxonin®, Loxonin® Pap, Loxonin® Tape) is a prodrug-type NSAID that is available in several formulations, including 60 mg tablets, 100 mg hydrogel patches and 50 or 100 mg tape. In active comparator-controlled trials, oral loxoprofen therapy (ranging from 2 days to 6 weeks’ duration depending on the pain type) provided analgesic efficacy that generally did not significantly differ from that of celecoxib for postoperative pain or frozen shoulder, ibuprofen for knee osteoarthritis or naproxen for lumbar pain. In double-blind, double-dummy, multicentre trials, loxoprofen hydrogel patches were noninferior to oral loxoprofen with regard to rates of final overall symptomatic improvement over 1–4 weeks in patients with knee osteoarthritis, myalgia or trauma-induced swelling and pain. Loxoprofen hydrogel patches were also noninferior to other commercially available patches (ketoprofen and indometacin) over 2 or 4 weeks in patients with knee osteoarthritis or myalgia in open-label studies. Oral and topical loxoprofen were generally well tolerated in clinical trials. Thus, loxoprofen is a useful analgesic option for patients with pain and inflammation, with topical loxoprofen potentially reducing the risk of gastrointestinal, cardiovascular and renal complications associated with oral NSAID use.The manuscript was reviewed by: X. Chen, Clinical Pharmacology Research Center, Peking Union Medical College Hospital, Beijing, China; H.-G. Xie, General Clinical Research Center, Nanjing First Hospital, Nanjing Medical University, Nanjing, China.